RxDoctor Payments Data

Michael Kissel, MD

Pain Medicine · Loganville, GANPI 1356542799

Payments from drug & device makers

$1,812in general payments, 2019–2025

Across 74 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$424
  • Collegium Pharmaceutical, Inc.$390
  • Pacira Pharmaceuticals Incorporated$338
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$252
  • Sentynl Therapeutics, Inc.$79
  • Forte Bio-pharma LLC$73
  • plus $257 from 10 others

What the payments were for

  • Travel & lodging$32518%
  • Food & beverage$1,48782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,812 in reported general payments places this provider in the 40th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$336,149
Medicare patients
272
Services billed
6,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine496$139,037
BelbucaBuprenorphine Hcl68$59,555
PercocetOxycodone Hcl/Acetaminophen11$48,764
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen985$37,518
LinzessLinaclotide37$34,309
Tramadol Hcl ErTramadol Hcl338$21,291
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen902$20,484
MovantikNaloxegol Oxalate30$15,437
Pregabalin819$14,555
Nucynta ErTapentadol Hcl13$14,413
Xtampza ErOxycodone Myristate33$13,777
OzempicSemaglutide16$12,961
Oxycodone Hcl579$12,213
Hydromorphone ErHydromorphone Hcl22$9,134
Gabapentin790$8,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er$390$87,744114 claims
AbbVieLinzess$24$34,30937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Loganville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →